Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit

被引:94
作者
Kodera, Y
Ito, S
Yamamura, Y
Mochizuki, Y
Fujiwara, M
Hibi, K
Ito, K
Akiyama, S
Nakao, A
机构
[1] Nagoya Univ, Sch Med, Dept Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Aichi Canc Ctr, Dept Surg Gastroenterol, Aichi, Japan
关键词
cancer recurrence; follow-up; gastrectomy; curative resection; gastric carcinoma;
D O I
10.1245/ASO.2003.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although routine follow-up to detect asymptomatic recurrence after surgery for gastric cancer is recommended, the effect of such reassessment on survival has not been evaluated. Methods: Clinical records of patients developing recurrent disease after potentially curative resection between 1985 and 1996 were retrieved. Among these patients, 197 were in our follow-up program. We analyzed survival in these patients according to the presence or absence of cancer-related symptoms when recurrent disease was diagnosed. Results: Of all patients with recurrent disease, 50% were diagnosed within 1 year and 75% within 2 years of surgery. Asymptomatic recurrence, detected in 88 patients (45%), frequently represented distant metastasis. Although early detection significantly improved survival after detection of recurrent disease, disease-free survival for this subset was shorter. Thus, no significant difference in overall survival was observed. Conclusions: Early detection of asymptomatic gastric cancer recurrence did not improve overall survival of patients with recurrence after curative resection. Until development of more effective treatment for this disease, close follow-up may offer no survival benefit.
引用
收藏
页码:898 / 902
页数:5
相关论文
共 14 条
[1]  
Böhner H, 2000, HEPATO-GASTROENTEROL, V47, P1489
[2]   Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer [J].
Boku, N ;
Ohtsu, A ;
Shimada, Y ;
Shirao, K ;
Seki, S ;
Saito, H ;
Sakata, Y ;
Hyodo, I .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :319-323
[3]   Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer [J].
Glimelius, B ;
Ekstrom, K ;
Hoffman, K ;
Graf, W ;
Sjoden, PO ;
Haglund, U ;
Svensson, C ;
Enander, LK ;
Linne, T ;
Sellstrom, H ;
Heuman, R .
ANNALS OF ONCOLOGY, 1997, 8 (02) :163-168
[4]  
GUNDERSON LL, 1995, CLIN ONCOLOGY, P1209
[5]   Evaluation of a follow-up programme after curative resection for colorectal cancer [J].
Howell, JD ;
Wotherspoon, H ;
Leen, E ;
Cooke, TC ;
McArdle, CS .
BRITISH JOURNAL OF CANCER, 1999, 79 (02) :308-310
[6]  
MURAD AM, 1993, CANCER, V72, P37, DOI 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO
[7]  
2-P
[8]  
*NCCN, 1998, ONCOLOGY HUNTINGT, V12, P179
[9]   RANDOMIZED COMPARISON OF FLUOROURACIL, EPIDOXORUBICIN AND METHOTREXATE (FEMTX) PLUS SUPPORTIVE CARE WITH SUPPORTIVE CARE ALONE IN PATIENTS WITH NONRESECTABLE GASTRIC-CANCER [J].
PYRHONEN, S ;
KUITUNEN, T ;
NYANDOTO, P ;
KOURI, M .
BRITISH JOURNAL OF CANCER, 1995, 71 (03) :587-591
[10]  
Saiura A, 2002, HEPATO-GASTROENTEROL, V49, P1062